The United Kingdom’s medicines regulator has authorized clinical trials for a novel Ebola vaccine developed by researchers at the University of Oxford, marking the first of four vaccines in development to advance to human testing.
The vaccine development began eight weeks prior following declaration of a public health emergency on 17 May. The outbreak, caused by the Bundibugyo species of Ebola and centered in the Democratic Republic of the Congo, has resulted in 625 deaths and 1,792 laboratory-confirmed cases to date. Scientists emphasize the urgency of vaccine development, as this particular Ebola species requires its own distinct treatments and vaccines, with no currently approved pharmaceuticals or immunizations available.
The initial phase of testing will involve 50 healthy adults aged 18-55 in the UK, with first doses expected within weeks. Trial participants will undergo monitoring for one year while researchers assess immune response and potential side effects. The Oxford team is simultaneously preparing for additional trials in Africa in collaboration with regional partners. The accelerated development timeline has been enabled by deployment of viral vector technology previously used in the Oxford-AstraZeneca COVID-19 vaccine. The technology utilizes a genetically modified chimpanzee cold virus as a delivery mechanism for genetic material from the Bundibugyo Ebola species, prompting immune system recognition without causing infection.
The vaccine candidate has undergone testing in mice and macaque monkeys prior to human trials. The Serum Institute of India has manufactured the vaccine to clinical standards and stockpiled approximately 620,000 doses. Researchers acknowledge that while the platform carries a theoretical risk similar to the COVID-19 vaccine variant—rare blood clots affecting up to one in 100,000 recipients—this risk remains substantially lower than the mortality rate from Bundibugyo Ebola infection, estimated at approximately one-third of infected individuals. Three additional vaccine candidates are under development by other organizations, including approaches utilizing mRNA technology and proven methodologies for alternative Ebola species variants.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI